Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 283,627 shares of the company’s stock after selling 3,146,628 shares during the period. CenterBook Partners LP owned approximately 0.18% of Humacyte worth $494,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HUMA. CWM LLC boosted its stake in shares of Humacyte by 29,921.4% in the second quarter. CWM LLC now owns 43,531 shares of the company’s stock valued at $91,000 after purchasing an additional 43,386 shares during the period. Savant Capital LLC acquired a new position in Humacyte in the 2nd quarter worth $122,000. Vanguard Personalized Indexing Management LLC purchased a new position in Humacyte in the 2nd quarter valued at about $30,000. SBI Securities Co. Ltd. grew its stake in shares of Humacyte by 6,305.4% during the second quarter. SBI Securities Co. Ltd. now owns 68,218 shares of the company’s stock valued at $143,000 after acquiring an additional 67,153 shares in the last quarter. Finally, Letko Brosseau & Associates Inc. increased its position in shares of Humacyte by 85.3% during the second quarter. Letko Brosseau & Associates Inc. now owns 45,950 shares of the company’s stock worth $96,000 after acquiring an additional 21,150 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Down 1.7%

Shares of NASDAQ:HUMA opened at $1.13 on Friday. The company’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.39. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte, Inc. has a 1-year low of $0.88 and a 1-year high of $3.94. The stock has a market capitalization of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday. Benchmark reduced their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, BTIG Research reiterated a “buy” rating and set a $6.00 price objective on shares of Humacyte in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

Humacyte Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.